Lomedeucitinib vs zasocitinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: TYK2 · full Psoriasis pipeline
Lomedeucitinib
Developed by Beeline Medicines under a licence from Bristol-Myers Squibb
NCT05730725 · Phase 2 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and included 109 participants, but each treatment group was relatively small. The clinical primary endpoint, PASI-75 response at week 12, favored BMS-986322 over placebo based on the reported rates, although statistical significance was not reported in the registry.
Reported efficacy
Percentage of Participants Achiving PASI-75 at Week 12 (12 Weeks); Number of Participants With Safety Related Events (approximately 85 days); Number of Participants With TEAE by Worst Intensity (approximately 5 months); Number of Participants With AE Indicating Clinical Laboratory Abnormality (approximately 5 months); Number of Participants With Clinically Significant Changes From Baseline in ECG Evaluations. (approximately 5 months); Number of Participants With Clinically Significant Changes From Baseline in Vital Signs Evaluations (approximately 5 months); Number of Participants With Clinically Significant Changes From Baseline in Physical Examination Evaluations (approximately 5 months): Percentage of Participants Achiving PASI-75 at Week 12 (12 Weeks): BMS-986322 16 mg 47.8% (95% CI 26.8 to 69.4) | BMS-986322 32 mg 80.8% (95% CI 60.6 to 93.4) | BMS-986322 64 mg 63% (95% CI 42.4 to 80.6) vs Placebo 3.6% (95% CI 0.1 to 18.3) (met)
Result source: NCT05730725
zasocitinib
Developed by Takeda Pharmaceutical Company
NCT06108544 · Phase 3 · completed
This randomized, quadruple-blind, placebo- and active-controlled Phase 3 trial (n=1,108) in moderate-to-severe plaque psoriasis found that zasocitinib produced clear or almost-clear skin in 69.2% of patients at week 16, compared with 12.6% on placebo (p<0.001).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: May 2027 · NCT07752108 (registry estimate)
Reported efficacy
Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI)-100 at Week 16: LATITUDE Atlas, PASI 100 at week 16: more than 35% of zasocitinib-treated patients achieved complete skin clearance (PASI 100), more than 2.5 times the response rate for deucravacitinib. (met)
Result source: NCT06973291
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Lomedeucitinib | zasocitinib |
|---|---|---|
| PASI 75 | 63% vs 3.6%+59.4 vs placeboNCT0573072517 other results
| 67.3% vs 5.8%+61.5 vs placeboNCT049998394 other results
|
| PASI 90 | 40.7% vs 3.6%+37.1 vs placeboNCT0573072517 other results
| 46.2% vs 0%+46.2 vs placeboNCT049998393 other results
|
| PASI 100 | 3.7% vs 0%+3.7 vs placeboNCT0573072517 other results
| 32.7% vs 0%+32.7 vs placeboNCT049998393 other results
|
| sPGA 0/1 | 55.6% vs 3.6%+52 vs placeboNCT057307252 other results
| 51.9% vs 3.8%+48.1 vs placeboNCT049998395 other results
|
| DLQI, change | —Not reported | -8.9 vs -4.9−4 vs placeboNCT049998393 other results
|
PASI 75
- Lomedeucitinib
- 63% vs 3.6%+59.4 vs placeboNCT05730725
17 other results
- 80.8% vs 3.6% NCT05730725
- 47.8% vs 3.6% NCT05730725
- 72% vs 4.2% NCT05730725
- 57.7% vs 4% NCT05730725
- 30.8% vs 3.6% NCT05730725
- 4% vs 0% NCT05730725
- 3.8% vs 0% NCT05730725
- 80.8% vs 4.2% NCT05730725
- 66.7% vs 4% NCT05730725
- 33.3% vs 3.6% NCT05730725
- 11.5% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 54.5% vs 4.2% NCT05730725
- 40% vs 4% NCT05730725
- 7.4% vs 3.6% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- zasocitinib
- 67.3% vs 5.8%+61.5 vs placeboNCT04999839
4 other results
- 67.9% vs 5.8% NCT04999839
- 44.2% vs 5.8% NCT04999839
- 18% vs 5.8% NCT04999839
- 75.7% vs 12.1% NCT06088043
PASI 90
- Lomedeucitinib
- 40.7% vs 3.6%+37.1 vs placeboNCT05730725
17 other results
- 48% vs 4.2% NCT05730725
- 30.8% vs 4% NCT05730725
- 7.7% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 61.5% vs 3.6% NCT05730725
- 61.5% vs 4.2% NCT05730725
- 25.9% vs 4% NCT05730725
- 18.5% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 13% vs 3.6% NCT05730725
- 13.6% vs 4.2% NCT05730725
- 8% vs 4% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- zasocitinib
- 46.2% vs 0%+46.2 vs placeboNCT04999839
3 other results
- 45.3% vs 0% NCT04999839
- 21.2% vs 0% NCT04999839
- 8% vs 0% NCT04999839
PASI 100
- Lomedeucitinib
- 3.7% vs 0%+3.7 vs placeboNCT05730725
17 other results
- 4% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 15.4% vs 0% NCT05730725
- 15.4% vs 0% NCT05730725
- 3.7% vs 0% NCT05730725
- 3.7% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- 0% vs 0% NCT05730725
- zasocitinib
- 32.7% vs 0%+32.7 vs placeboNCT04999839
3 other results
- 15.1% vs 0% NCT04999839
- 9.6% vs 0% NCT04999839
- 2% vs 0% NCT04999839
sPGA 0/1
- Lomedeucitinib
- 55.6% vs 3.6%+52 vs placeboNCT05730725
2 other results
- 69.2% vs 3.6% NCT05730725
- 54.2% vs 3.6% NCT05730725
- zasocitinib
- 51.9% vs 3.8%+48.1 vs placeboNCT04999839
5 other results
- 49.1% vs 3.8% NCT04999839
- 26.9% vs 3.8% NCT04999839
- 10% vs 3.8% NCT04999839
- 69.2% vs 12.6% NCT06108544
- 71.4% vs 10.7% NCT06088043
DLQI, change
- Lomedeucitinib
- —Not reported
- zasocitinib
- -8.9 vs -4.9−4 vs placeboNCT04999839
3 other results
- -8.5 vs -4.9 NCT04999839
- -7.9 vs -4.9 NCT04999839
- -5.3 vs -4.9 NCT04999839
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Lomedeucitinib: 3 of 4 rows · zasocitinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Lomedeucitinib | zasocitinib |
|---|---|---|
| Dropout rate | 7.4%BMS-986322 64 mg NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 show 2 more results3.7%BMS-986322 32 mg NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 3.7%BMS-986322 16 mg NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 | 9.6%30 mga NCT04999839 · Phase 2 · registry result, not featured evidence show 3 more results13.2%15 mg NCT04999839 · Phase 2 · registry result, not featured evidence 13.5%5 mg NCT04999839 · Phase 2 · registry result, not featured evidence 16%2 mg NCT04999839 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —BMS-986322 64 mg NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 show 2 more results—BMS-986322 32 mg NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 —BMS-986322 16 mg NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 | 1.9%30 mga NCT04999839 · Phase 2 · registry result, not featured evidence show 3 more results1.9%15 mg NCT04999839 · Phase 2 · registry result, not featured evidence 1.9%5 mg NCT04999839 · Phase 2 · registry result, not featured evidence 2%2 mg NCT04999839 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 0%BMS-986322 64 mg NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 show 2 more results0%BMS-986322 32 mg NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 3.7%BMS-986322 16 mg NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 | 0%30 mga NCT04999839 · Phase 2 · registry result, not featured evidence show 3 more results1.9%15 mg NCT04999839 · Phase 2 · registry result, not featured evidence 0%5 mg NCT04999839 · Phase 2 · registry result, not featured evidence 0%2 mg NCT04999839 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | acne 14.8% (placebo 0%) covid-19 11.1% (placebo 0%) dermatitis acneiform 7.4% (placebo 0%) NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 show 2 more resultsaphthous ulcer 11.1% (placebo 0%) folliculitis 11.1% (placebo 0%) upper respiratory tract infection 7.4% (placebo 0%) NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 diarrhoea 7.4% (placebo 0%) headache 7.4% (placebo 0%) influenza 7.4% (placebo 3.6%) NCT05730725 · Phase 2 · monotherapy · Psoriasis · phase 2 | 30 mga covid-19 13.5% (placebo 1.9%) blood creatine phosphokinase increased 5.8% (placebo 3.8%) dermatitis acneiform 5.8% (placebo 0%) NCT04999839 · Phase 2 · registry result, not featured evidence show 3 more results15 mg covid-19 11.3% (placebo 1.9%) acne 5.7% (placebo 0%) blood creatine phosphokinase increased 5.7% (placebo 3.8%) NCT04999839 · Phase 2 · registry result, not featured evidence 5 mg covid-19 7.7% (placebo 1.9%) lymphocyte count decreased 5.8% (placebo 0%) blood creatine phosphokinase increased 3.8% (placebo 3.8%) NCT04999839 · Phase 2 · registry result, not featured evidence 2 mg covid-19 12% (placebo 1.9%) alanine aminotransferase increased 6% (placebo 0%) diarrhoea 6% (placebo 1.9%) NCT04999839 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Lomedeucitinib
show 17 more results
show 14 more results
zasocitinib
show 3 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lomedeucitinib's landscape · zasocitinib's landscape